A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance

Journal of Investigative Dermatology

Volumn 134, Issue 2, 2014, Pages 553-556

  Miura, Shinpei ^a   Shibazaki, Masahiko ^a   Kasai, Shuya ^a   Yasuhira, Shinji ^a   Watanabe, Ayano ^a   Inoue, Tsuyoshi ^a   Kageshita, Yuich ^a   Tsunoda, Kanako ^a   Takahashi, Kazuhiro ^a   Akasaka, Toshihide ^a   Masuda, Tomoyuki ^a   Maesawa, Chihaya ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; GENOMIC DNA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; UBIQUITIN;

ALLELE; CODON; CUTANEOUS MELANOMA; DRUG RESISTANCE; HUMAN; LETTER; MELANOMA; MELANOSOME; MISSENSE MUTATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; STOP CODON;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FRAMESHIFT MUTATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOMA; MUTATION, MISSENSE; NF-E2-RELATED FACTOR 2; SKIN NEOPLASMS;

EID: 84892817921     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.343     Document Type: Letter

References (15)

1. Bradford PT, Goldstein AM, McMaster ML, Tucker MA (2009) Acral lentiginous melanoma: Incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 145: 427-34
2. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F et al. (2006) Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 103:9903-7
3. Deavall DG, Martin EA, Horner JM, Roberts R (2012) Drug-induced oxidative stress and toxicity. J Toxicol 2012:1-13
4. Flaherty KT (2010) Narrative review: BRAF opens the door for therapeutic advances in melanoma. Ann Intern Med 153:587-91
5. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: Role of Atp-dependent transporters. Nat Rev Cancer 2:48-58
6. Grossman D, Altieri DC (2001) Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20:3-11
7. Huang V, Hepper D, Anadkat M, Cornelius L (2012) Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 148:628-33
8. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 107:14903-8
9. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H et al. (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming Cancer Cell 22:66-79
10. Saldanha G, Potter L, DaForno P, Pringle JH (2006) Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 12:4499-505
11. Sekhar KR, Yan XX, Freeman ML (2002) Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene 21: 6829-34
12. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M et al. (2008) Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135(1358-68):e4
13. Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16:123-40
14. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S et al. (2008) From the cover: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-6
15. Zhang WB, Wang Z, Shu F, YH Jin, HY Liu, QJ Wang et al. (2010) Activation of AMP-Activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem 285:40461-71